The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy. To treat the disease successfully, new therapeutic strategies are urgently needed. One of these strategies can be the use of neurokinin-1 receptor (NK-1R) antagonists (e.g., aprepitant), because the substance P (SP)/NK-1R syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz, Miguel, Coveñas, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355887/
https://www.ncbi.nlm.nih.gov/pubmed/32492831
http://dx.doi.org/10.3390/jcm9061659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355887/
https://www.ncbi.nlm.nih.gov/pubmed/32492831
http://dx.doi.org/10.3390/jcm9061659

Ejemplares similares